NCT00186589

90Y-IBRITUMOMAB Tiuxetan and AHCI With HD Chemotherapy and Autologous Transplantation for Relapsed or Resistant NHL

90Y-Ibritumomab Tiuxetan and Autologous Hematopoietic Cell Infusion Followed by High Dose Chemotherapy and Autologous Transplantation for Relapsed or Resistant Non-Hodgkin's Lymphoma

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 30 (estimated)
• Sponsor: Stanford University · Academic / Other
• Sex: All
• Age: 18 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

To test a new way to approach hematopoietic stem cell transplantation for Relapsed or Resistant Non-Hodgkin's Lymphoma.

Detailed description

This is a single center phase I dose escalation trial of a single course of IDEC-Y2B8 (90Y-ibritumomab tiuxetan, Zevalin) with autologous peripheral blood progenitor cell infusion followed by high dose chemotherapy and AHCT for patients with relapsed or refractory B-cell NHL. In step one, an imaging dose of IDEC-In2B8 (111In- ibritumomab tiuxetan, Zevalin) will be followed one week later by IDEC-Y2B; both will be preceded by an infusion of 250 mg/m2 rituximab. Imaging will be done immediately (within 1 hr), at 4 - 6 hours and at 1, 3, and 6 days after 90Y-ibritumomab tiuxetan.

Conditions

• Lymphoma, Non-Hodgkin
• Blood and Marrow Transplant (BMT)

Interventions

Type	Name	Description
DRUG	90Y Ibritumomab tiuxetan

Timeline

• Start date: 2004-05-01
• Primary completion: 2007-07-01
• Completion: 2007-07-01
• First posted: 2005-09-16
• Last updated: 2012-06-06

Locations

1 site across 1 country: United States